Melanoma recurrent

6 trials MedDRA PT
6 Registered trials
0 Recruiting
5 Unique sponsors
6 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 2 substances
Phase III: 1 Phase II: 2 Phase I/II: 1 Phase I (First in Human): 1 Other: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended

Phase II

2 trials
  • Genentech Inc. Commercial
    AUTOGENE CEVUMERAN; PEMBROLIZUMAB
    2023-507389-15-00 2 countries 2020 n=60
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended

Phase I/II

1 trial
  • Glaxosmithkline Research & Development Limited Commercial
    COBOLIMAB; DOSTARLIMAB
    2024-511350-41-00 6 countries 2025 n=46
    Ended

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended

Other

1 trial
  • Formycon AG Commercial
    IMP not specified
    2023-509765-20-00 5 countries 2024 n=116
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase II, Phase III 0
Formycon AG Commercial 1 Other 0
Genentech Inc. Commercial 1 Phase II 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase I/II 0
New trials by year
2020
1
2021
1
2022
1
2023
1
2024
1
2025
1
← All indication landscapes